AURA3 Clinical Study Data – TAGRISSO® (osimertinib)
A trial of osimertinib for non small cell lung cancer (AURA3) | Cancer Research UK
Molecularly targeted therapies in non-small cell lung cancer: The evolving role of tyrosine kinase inhibitors Doval D C, Desai C J, Sahoo T P - Indian J Cancer
Clinical Trials with Osimertinib | Download Scientific Diagram
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer | NEJM
FP16.03 Early Circulating-Tumor DNA EGFR Mutation Clearance in Plasma as a Predictor of Clinical Outcomes in The AURA3 Trial - Journal of Thoracic Oncology
Osimertinib (AZD9291)—a science-driven, collaborative approach to rapid drug design and development - Annals of Oncology
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study - The Lancet Oncology
AURA3 Clinical Study Data – TAGRISSO® (osimertinib)
Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC - ScienceDirect
Coronavirus & Aura Air - Results of Clinical Trials - AURA AIR UK - SAFER & CLEANER AIR
Asia Pacific Biotech News
Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial -
Osimertinib vs Platinum/Pemetrexed and Overall Survival in Patients With EGFR T790M Advanced NSCLC: AURA3 Trial
Frontiers | Patterns and Treatment Strategies of Osimertinib Resistance in T790M-Positive Non-Small Cell Lung Cancer: A Pooled Analysis
Tagrisso demonstrates superiority over chemotherapy in EGFR T790M mutation-positive non-small cell lung cancer
Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC | Scientific Reports
AURA3 Clinical Study Data – TAGRISSO® (osimertinib)
Beyond disease-progression: Clinical outcomes after EGFR-TKIs in a cohort of EGFR mutated NSCLC patients | PLOS ONE
Aurinia And Voclosporin In Lupus Nephritis: The Countdown Begins (NASDAQ:AUPH) | Seeking Alpha
Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component | Journal of Clinical Oncology
Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non–small-cell Lung Cancer: LAURA Trial in Progress - Clinical Lung Cancer
AURA3 Clinical Study Data – TAGRISSO® (osimertinib)
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer | NEJM
d.planchard on Twitter: "Important result awaiting in EGFR mut pts :OS of AURA3 trial : just confirm to use osimertinib first line @myESMO #esmoasia19 https://t.co/Dwh04T0C4N" / Twitter
